John C. Byrd
The Ohio State University · 1,529 works · 82,147 citations · h-index 130
Top works
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
- Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
- Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
- Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study
- ZAP-70 Compared with Immunoglobulin Heavy-Chain Gene Mutation Status as a Predictor of Disease Progression in Chronic Lymphocytic Leukemia
- Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic Leukemia
- iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
- Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
- Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
- Extramedullary myeloid cell tumors in acute nonlymphocytic leukemia: a clinical review.
- Rituximab Using A Thrice Weekly Dosing Schedule in B-Cell Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Demonstrates Clinical Activity and Acceptable Toxicity
- Rituximab Therapy in Hematologic Malignancy Patients With Circulating Blood Tumor Cells: Association With Increased Infusion-Related Side Effects and Rapid Blood Tumor Clearance
- Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib
- Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
- Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies
- Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
- International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia
- CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability